Pulmonary sarcoidosis in the context of a telaprevir-based triple therapy for hepatitis C

Rev Port Pneumol (2006). 2016 Jan-Feb;22(1):57-9. doi: 10.1016/j.rppnen.2015.08.004. Epub 2015 Oct 5.

Authors

D Pérez Parente¹, M Suárez Santamaría², S Suárez Ordóñez³, L E Morano Amado⁴

Affiliations

¹ Pharmacy Service, Hospital Meixoeiro, EOXI Vigo, Vigo, Spain. Electronic address: di_parente@hotmail.com.
² Pharmacy Service, Hospital Meixoeiro, EOXI Vigo, Vigo, Spain.
³ Hematology Service, Hospital Meixoeiro, EOXI Vigo, Vigo, Spain.
⁴ Unit of Infectious Disease, Hospital Meixoeiro, EOXI Vigo, Vigo, Spain.

PMID: 26422338
DOI: 10.1016/j.rppnen.2015.08.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antiviral Agents / adverse effects*
Emtricitabine / adverse effects
Hepatitis C, Chronic / drug therapy
Humans
Male
Middle Aged
Oligopeptides / adverse effects*
Oligopeptides / therapeutic use
Raltegravir Potassium / adverse effects
Sarcoidosis, Pulmonary / chemically induced*

Substances

Antiviral Agents
Oligopeptides
Raltegravir Potassium
telaprevir
Emtricitabine